Nashville Area ETF(NASH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NASH Nashville Area ETF

盘前交易 07-11 05:31:23 EDT

29.00

+0.00

0.00%

最高29.00	最低29.00	成交量0.00
今开29.00	昨收29.00	日振幅0.00%
总市值0.00	流通市值0.00	总股本0.00
成交额0.00	换手率--	流通股本0.00
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NASH","market":"US","secType":"STK","nameCN":"Nashville Area ETF","latestPrice":29,"timestamp":1519246800000,"preClose":29,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"盘前交易","change":0,"latestTime":"07-11 05:31:23 EDT","open":29,"high":29,"low":29,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752240600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":29,"volumeRatio":0},"requestUrl":"/m/hq/s/NASH","defaultTab":"news","newsList":[{"id":"2293588547","title":"百亿NASH用药，歌礼制药-B（01672）布局多靶点有望拔得头筹","url":"https://stock-news.laohu8.com/highlight/detail?id=2293588547","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2293588547?lang=zh_cn&edition=full","pubTime":"2022-12-22 18:45","pubTimestamp":1671705927,"startTime":"0","endTime":"0","summary":"NASH 治疗领域再起波澜。接连公布的临床突破以及BD活动也将NASH新药研发推向市场风口。未来NASH 将会成为更加普遍的世界性肝病，将取代丙肝成为需要进行肝移植手术的主要疾病。由于NASH患者人数众多，并且疾病不可逆转理应终身服药，因此NASH的药物拥有十分广阔的前景。布局THR-β、FASN及FXR多靶点，歌礼制药有望拔得国内NASH产品的头筹百亿蓝海市场，引得国内药企纷纷布局。口服小分子ASC42靶向FXR，被美国FDA纳入快速通道，目前已经完成I期临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/851572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1161","01477","BK1191","BK1574","BK1515","NASH"],"gpt_icon":0},{"id":"2293311862","title":"四十年研发坟场 NASH药物的果子眼看就要熟了","url":"https://stock-news.laohu8.com/highlight/detail?id=2293311862","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2293311862?lang=zh_cn&edition=full","pubTime":"2022-12-21 10:38","pubTimestamp":1671590281,"startTime":"0","endTime":"0","summary":"经过四十年风雨飘摇后，这个价值百亿美金的NASH药物市场，终于准备迎来新希望了。/ 01 /四十年研发坟场NASH药物的研发，可以说是慢性病领域的坟场。目前，在NASH领域最广泛接受的发病机制是二次打击假说。与人数对应的是NASH治疗药物的潜在市场规模。这也就意味着，率先摘取NASH药物胜利果实的药企，将会获得丰厚的回报。回到国内市场来说，NASH治疗市场同样吸引了众多选手入局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8LtRdkeswy2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["NASH"],"gpt_icon":0},{"id":"2293362426","title":"歌礼(1672.HK)NASH研发管线创新药ASC41(THRβ) II期入组顺利推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2293362426","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2293362426?lang=zh_cn&edition=full","pubTime":"2022-12-21 08:15","pubTimestamp":1671581723,"startTime":"0","endTime":"0","summary":"中国杭州和绍兴，2022年12月21日―歌礼制药有限公司的全资子公司甘莱制药有限公司自主研发的甲状腺激素受体β激动剂ASC41用于治疗肝穿活检证实的非酒精性脂肪性肝炎患者的52周II期临床试验入组顺利推进。ASC41 II期临床试验是由中国生物技术公司发起的目前进展最快的疗程为52周入组肝穿活检证实NASH患者的II期临床试验，于2022年10月初完成首例患者入组。2021年2月，歌礼宣布ASC41在超重和肥胖受试者中取得的良好的临床试验结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2022/12/21081537227248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01672","BK1574","BK4096","06978","THR","NASH","159992","BK1515","BK1161"],"gpt_icon":0},{"id":"2292382921","title":"美股龙头单日暴涨268%，刚刚取得重大医疗突破的NASH是什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2292382921","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2292382921?lang=zh_cn&edition=full","pubTime":"2022-12-20 15:08","pubTimestamp":1671520118,"startTime":"0","endTime":"0","summary":"华创证券表示，本次MDGL的积极数据达到了FDA要求的MASH药物审批的金标准，预计将成为全球首个NASH药物，潜在市场有望达到百亿美元级别，NASH大潮来临。","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/ad0d886c-26e8-465d-9135-31ec519ea213.jpeg?imageView2/1/w/340/h/340","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/ad0d886c-26e8-465d-9135-31ec519ea213.jpeg?imageView2/1/w/340/h/340"],"rights":{"source":"wallstreetcn_api","url":"https://wallstreetcn.com/articles/3677905","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3677905","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_api","symbols":["NASH"],"gpt_icon":0},{"id":"2292383788","title":"全球首款NASH新药超预期成功，百亿美元领域，国内谁能跟上？| 见智研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2292383788","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2292383788?lang=zh_cn&edition=full","pubTime":"2022-12-20 11:47","pubTimestamp":1671508029,"startTime":"0","endTime":"0","summary":"在上百款药物失败后，百亿NASH领域终于迎来第一款新药。","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/8fc36ecf-6bf4-42f8-a388-05e93413f428.jpeg?imageView2/1/w/340/h/340","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/8fc36ecf-6bf4-42f8-a388-05e93413f428.jpeg?imageView2/1/w/340/h/340"],"rights":{"source":"wallstreetcn_api","url":"https://wallstreetcn.com/articles/3677894","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3677894","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_api","symbols":["NASH"],"gpt_icon":0},{"id":"2281862696","title":"歌礼制药(01672.HK)治疗脂肪性肝炎药物具良好耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=2281862696","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2281862696?lang=zh_cn&edition=full","pubTime":"2022-11-07 08:42","pubTimestamp":1667781758,"startTime":"0","endTime":"0","summary":"歌礼制药－Ｂ  公布，ASC43F治疗非酒精性脂肪性肝炎(NASH)的I期单剂量研究摘要，已在2022年美国肝病研究协会(AASLD)年会(The Liver Meeting?2022)上以壁报形式报告。公司指出，有关I期研究表明，ASC43F显示出良好的耐受性和安全性，ASC43F中的ASC41/ASC41A和ASC42的药代动力学(PK)参数与ASC41和ASC42作为单药治疗的PK相似。ASC43F是用於NASH治疗的固定剂量复方制剂(FDC)，每日用药一次，每次一片，这将改善患者的依从性。(jl/w)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1224473&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["FDC","BK4181","01672","NASH","BK1574","PK","BK1161","BK1515"],"gpt_icon":0},{"id":"2281256476","title":"歌礼制药-B(01672)：在AASLD年会以壁报形式报告ASC43F治疗 NASH的I期单剂量研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2281256476","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2281256476?lang=zh_cn&edition=full","pubTime":"2022-11-07 08:18","pubTimestamp":1667780283,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，ASC43F治疗非酒精性脂肪性肝炎(NASH)的I期单剂量研究摘要已在2022年美国肝病研究协会(AASLD)年会(The Liver Meeting® 2022)上以壁报形式报告。该等研究结果研究表明，ASC43F显示出良好的耐受性和安全性，ASC43F中的ASC41/ ASC41A和ASC42的药代动力学(PK)参数与ASC41和ASC42作为单药治疗的PK相似。ASC43F是用于NASH治疗的固定剂量复方制剂(FDC)，每日用药一次，每次一片，这将改善患者的依从性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/824654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","01672","BK1574","01477","BK1161","NASH"],"gpt_icon":0},{"id":"2280523375","title":"歌礼制药－Ｂ(01672.HK)合作夥伴治疗脂肪性肝炎药物临床试验取得积极期中数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2280523375","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2280523375?lang=zh_cn&edition=full","pubTime":"2022-11-04 08:59","pubTimestamp":1667523592,"startTime":"0","endTime":"0","summary":"歌礼制药－Ｂ  公布，其战略合作夥伴Sagimet Biosciences宣布，脂肪酸合成酶抑制剂ASC40 治疗非酒精性脂肪性肝炎患者2b期临床试验取得积极期中数据。数据显示，NASH各项关键标志物有统计学意义上的显着减少，包括肝脏脂肪含量、炎症和纤维化标志物，这进一步验证早期研究中观察到的结果。牛津大学访问学者、Pinnacle研究中心医学主任Stephen Harrison将於11月4至8日在美国华盛顿特区举办的美国肝病研究协会年会上就该研究的期中数据要点做口头报告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1224144&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["NASH","01672","BK1574","BK1515","BK1161"],"gpt_icon":0},{"id":"2280540320","title":"歌礼制药-B(01672)：脂肪酸合成酶抑制剂ASC40(Denifanstat)治疗非酒精性脂肪性肝炎(NASH)患者2b期临床试验取得积极期中数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2280540320","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2280540320?lang=zh_cn&edition=full","pubTime":"2022-11-04 08:20","pubTimestamp":1667521220,"startTime":"0","endTime":"0","summary":"歌礼制药-B(01672)发布公告，歌礼战略合作伙伴Sagimet Bioscie...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_16.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_16.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/823709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1576","BK1141","BK1515","BK1191","01672","03347","BK1574","NASH","01477","BK1161","BK1583"],"gpt_icon":0},{"id":"2273898955","title":"歌礼制药(01672.HK)治疗非酒精性脂肪性肝炎药物完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2273898955","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2273898955?lang=zh_cn&edition=full","pubTime":"2022-10-05 08:13","pubTimestamp":1664928808,"startTime":"0","endTime":"0","summary":"歌礼制药－Ｂ  公布，甲状腺激素受体β (THRβ)激动剂ASC41用於治疗肝穿活检证实的非酒精性脂肪性肝炎(NASH)患者的52周II期临床试验完成首例患者给药。ASC41 II期临床试验是由中国生物技术公司发起的目前进展最快的疗程为52周入组肝穿活检证实NASH患者的II期临床试验。II期临床试验将入组约180名肝穿活检证实的NASH患者，以1:1:1的比例随机分配进入两个药物组和一个安慰剂对照组，并接受一日一次口服ASC41(2毫克或4毫克)或安慰剂，治疗期52周。患者入组预计於2023年第三季完成。(jl/w)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1217202&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["BK1161","NASH","01672","BK1574","BK1515"],"gpt_icon":0},{"id":"2269125597","title":"下一个“百亿药”竞逐提速 中生制药收购NASH新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2269125597","media":"证券时报·e公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2269125597?lang=zh_cn&edition=full","pubTime":"2022-09-22 20:20","pubTimestamp":1663849200,"startTime":"0","endTime":"0","summary":"继PD-1、ADC、CAR-T“大战”后，谁会成为百亿药物的下一城，一直是萦绕产业的重要课题。从多药企新动作来看，NASH药物正在成为重要方向。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202209222515823974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","NASH","BK1191","01477"],"gpt_icon":0},{"id":"2269141171","title":"瞄准百亿市场 中国生物制药布局NASH创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2269141171","media":"上海证券报·中国证券网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2269141171?lang=zh_cn&edition=full","pubTime":"2022-09-22 17:41","pubTimestamp":1663839660,"startTime":"0","endTime":"0","summary":"中国生物制药9月22日发布公告称，公司下属企业正大天晴与法国生物科技公司Inventiva(IVA)签署协议，将获得治疗非酒精性脂肪性肝炎治疗药物lanifibranor在大中华区的独家许可权益，该药...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202209222515736884.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202209222515736884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","01177","BK1191","BK1521","06978","BK1589","BK1515","NASH","BK1161"],"gpt_icon":0},{"id":"2269145033","title":"中生制药(01177.HK)附属获「拉尼兰诺」大中华区开发生产商业化独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2269145033","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2269145033?lang=zh_cn&edition=full","pubTime":"2022-09-22 16:35","pubTimestamp":1663835721,"startTime":"0","endTime":"0","summary":"中生制药  宣布，附属公司正大天晴药於9月21日与Inventiva S.A.签订正式许可协议，可於中国大陆、香港、澳门、台湾开发、生产并商业化用於治疗非酒精性脂肪性肝炎和其他潜在的代谢疾病的「拉尼兰诺」。该产品在大中华区获批上市後，正大天晴将支付额外商业化里程碑付款及基於大中华区销售净额的分层提成。中生制药透露，拉尼兰诺目前正在美国进行III期临床试验，将有望成为第一个获得FDA批准治疗NASH的口服药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1215012&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["BK1515","01177","NASH","BK1521","BK1191","BK1589"],"gpt_icon":0},{"id":"2267468255","title":"人民金融·创新药指数涨0.49% | NASH新药迎来里程碑，国内创新药企向高悬果实冲锋","url":"https://stock-news.laohu8.com/highlight/detail?id=2267468255","media":"证券时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2267468255?lang=zh_cn&edition=full","pubTime":"2022-09-15 16:59","pubTimestamp":1663232366,"startTime":"0","endTime":"0","summary":"日前，美国生物技术公司Akero发布了其NASH新药的积极数据，受到业内广泛关注，该药被认为有望给全球NASH患者带来历史性的改变。受这些因素推动，新发布周期内，“人民金融·创新药指数”上涨了0.49%，最新报2890.51点。9月13日，一家名为Akero Therapeutics的生物技术公司宣布其NASH新药efruxifermin取得重要进展。若此结果在未来进一步获得证实，将有望为全球NASH患者带来历史性的改变。在我国，NASH的发病率已超过全球发病率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2022-09-15/doc-imqmmtha7435242.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2022-09-15/doc-imqmmtha7435242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["159992","NASH","BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2266829294","title":"石药集团(01093.HK)TG103注射液获批进行治疗NASH临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2266829294","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2266829294?lang=zh_cn&edition=full","pubTime":"2022-09-09 17:11","pubTimestamp":1662714685,"startTime":"0","endTime":"0","summary":"石药集团  公布，旗下1类生物制品创新药「TG103注射液」，近日已获得国家药品监督管理局批准，可在中国开展用於治疗非酒精性脂肪性肝炎(NASH)的临床试验。(gc/w)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1212733&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["NASH","01093"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":0.0377},{"period":"3month","weight":0.1721},{"period":"6month","weight":0.0781},{"period":"1year","weight":0.1149},{"period":"ytd","weight":0.0678}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"exchange":"ARCA","name":"Nashville Area ETF","nameEN":"LocalShares Nashville Area ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nashville Area ETF(NASH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nashville Area ETF(NASH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nashville Area ETF,NASH,Nashville Area ETF股票,Nashville Area ETF股票老虎,Nashville Area ETF股票老虎国际,Nashville Area ETF行情,Nashville Area ETF股票行情,Nashville Area ETF股价,Nashville Area ETF股市,Nashville Area ETF股票价格,Nashville Area ETF股票交易,Nashville Area ETF股票购买,Nashville Area ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nashville Area ETF(NASH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nashville Area ETF(NASH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}